{"nctId":"NCT03447249","briefTitle":"A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","startDateStruct":{"date":"2018-03-07","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":385,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"VX-659/TEZ/IVA TC","type":"EXPERIMENTAL","interventionNames":["Drug: VX-659/TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"VX-659/TEZ/IVA","otherNames":["VX-659/VX-661/VX-770","VX-659/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Heterozygous for F508del and an MF mutation (as defined in the protocol)\n* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height\n\nKey Exclusion Criteria:\n\n* Clinically significant cirrhosis with or without portal hypertension\n* Lung infection with organisms associated with a more rapid decline in pulmonary status\n* Solid organ or hematological transplantation\n\nOther protocol defined Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.6"},{"groupId":"OG001","value":"13.0","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.6"},{"groupId":"OG001","value":"13.4","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Number of Pulmonary Exacerbations (PEx)","description":"Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.0"},{"groupId":"OG001","value":"-44.6","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"1.1"},{"groupId":"OG001","value":"18.6","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Body Mass Index (BMI)","description":"BMI was defined as weight in kilogram (kg) divided by height in square meter (m\\^2).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.07"},{"groupId":"OG001","value":"1.06","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride","description":"Sweat samples were collected using an approved collection device.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.0"},{"groupId":"OG001","value":"-43.3","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.2"},{"groupId":"OG001","value":"18.0","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Time-to-first Pulmonary Exacerbation (PEx)","description":"Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in BMI Z-score for Participants <=20 Years of Age at Baseline","description":"BMI was defined as weight in kg divided by height in m\\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.05"},{"groupId":"OG001","value":"0.31","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Body Weight","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.2"},{"groupId":"OG001","value":"3.3","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Pre-dose Concentration (Ctrough) of VX-659, TEZ, M1-TEZ, and IVA","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"662","spread":"528"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"764","spread":"1520"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"614","spread":"519"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"638","spread":"521"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1220","spread":"645"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1390","spread":"1250"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1290","spread":"766"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1220","spread":"654"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4380","spread":"1560"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4580","spread":"1480"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4580","spread":"1530"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4420","spread":"1520"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"442","spread":"277"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"548","spread":"1100"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"429","spread":"327"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"416","spread":"303"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":58,"n":189},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Sputum increased","Headache","Upper respiratory tract infection"]}}}